Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Agios Pharmaceuticals's pe ratio was 3.9× on Oct 31, 2025, against 0.8× a year earlier. Over the last 2 years it ranged from 0.8× to 5.2×, with a median of 2.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Oct 31, 2025 | 3.9× | +1.0 |
| 2024 | Dec 31, 2024 | 2.9× | +2.1 |
| 2022 | Apr 29, 2022 | 0.8× | −0.6 |
| 2021 | Dec 31, 2021 | 1.5× | – |
See a number that looks wrong?